News

Virginia Beach, VA – July 15, 2025 – Aceso Plasma Inc., which develops cold plasma medical and decontamination technology, today announced it has successfully closed a Series A Preferred funding round of $500,000, led by Stony Lonesome Group, LLC. This milestone will support the next phase of clinical trials, regulatory advancement, and production development of Aceso’s oxygen-based cold plasma systems.

Sean Drake, Founder of Stony Lonesome Group, said: “We are thrilled to support Aceso Plasma. Founded by former Navy SEALs, the company exemplifies the kind of veteran-led innovation that Stony Lonesome Group has championed for over 14 years through our Mission-Focused investment thesis. The Aceso Plasma technology has significant potential across the spectrum of applications – ranging from emergency battlefield treatment to use in advanced medical facilities.”

“This closing will serve to further Aceso’s mission to develop cold plasma solutions intended for wound care, hemorrhage control, and decontamination,” said Zach Steinbock, CEO of Aceso Plasma. “We’re honored to have Stony Lonesome Group - a proven leader in early-stage defense and dual-use investments - guiding this round and supporting our development”

About Aceso Plasma Inc.

Based in Virginia Beach, VA, Aceso Plasma Inc. is focused on developing cold plasma solutions for medical and decontamination applications. The company’s proprietary ACP technology is protected by multiple issued patents and designed for adoption across both civilian and defense sectors. Learn more at www.acesoplasma.com.

 

Important Notices: This press release is for informational purposes only and is not an advertisement, offer to sell, or solicitation of an offer to buy any securities. The Aceso Plasma medical device technology is currently in development and has not yet commenced with clinical trials. Any statements regarding potential medical applications have not been evaluated by the FDA and the technology is not yet approved for medical use.

Forward-Looking Statements: This press release contains forward-looking statements regarding the company’s business plans, clinical development, and market opportunities. Actual results may differ materially from those projected. These statements are based on current expectations and involve risks and uncertainties.

Burn wound healing can be significantly delayed by infection leading to increased morbidity and hypertrophic scarring. An optimal antimicrobial agent would have the ability to kill bacteria without negatively affecting the host skin cells that are required for healing. Currently available products provide antimicrobial coverage, but may also cause reductions in cell proliferation and migration. Cold atmospheric plasma is a partially ionized gas that can be produced under atmospheric pressure at room temperature. In this study a novel handheld Aceso Plasma Generator was used to produce and test Aceso Cold Plasma (ACP) in vitro and in vivo. ACP showed a potent ability to eliminate bacterial load in vitro for a number of different species. Deep partial-thickness and full-thickness wounds that were treated with ACP after burning, after excision, after autografting, and at days 5, 7, and 9 did not show any negative effects on their wound healing trajectories. On par with in vitro analysis, bioburden was decreased in treated wounds vs. control. In addition, metrics of hypertrophic scar such as dyschromia, elasticity, trans-epidermal water loss (TEWL), and epidermal and dermal thickness were the same between the two treatment groups. It is likely that ACP can be used to mitigate the risk of bacterial infection during the phase of acute burn injury while patients await surgery for definitive closure. It may also be useful in treating wounds with delayed re-epithelialization that are at risk for infection and hypertrophic scarring. A handheld cold plasma device will be useful in treating all manner of wounds and surgical sites in order to decrease bacterial burden in an efficient and highly effective manner without compromising wound healing.

Read more